Drug Profile

MG 1124

Alternative Names: MG1124

Latest Information Update: 28 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GC Pharma
Developer GC Biopharma
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action CD66 antigen inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Lung cancer

Most Recent Events

28 Apr 2023 No recent reports of development identified for preclinical development in Lung-cancer in South Korea (Parenteral, Injection)
29 Mar 2022 GC Pharma is now called to GC Biopharma
18 Feb 2020 MG 1124 is available for licensing as of 20 Feb 2020 (GC Pharma website, February 2020) http://www.globalgreencross.com/eng/research/collaboration.do

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com